Walleye Capital
ALNY icon

Walleye Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Walleye Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.2M Buy
4,864
+1,709
+54% +$435K ﹤0.01% 3293
2026
Q2 		$950K Buy
3,155
+516
+20% +$156K ﹤0.01% 2173
2026
Q1 		$873K Sell
2,639
-3,329
-56% -$1.13M ﹤0.01% 2201
2025
Q4 		$2.37M Sell
5,968
-16,377
-73% -$7.25M 0.01% 1743
2025
Q3 		$10.2M Sell
22,345
-16,370
-42% -$6.67M 0.04% 541
2025
Q2 		$12.6M Buy
38,715
+36,345
+1,534% +$10.1M 0.05% 406
2025
Q1 		$640K Sell
2,370
-17,746
-88% -$4.56M ﹤0.01% 2350
2024
Q4 		$4.73M Buy
20,116
+16,467
+451% +$4.33M 0.01% 1112
2024
Q3 		$1M Sell
3,649
-66,658
-95% -$17.4M ﹤0.01% 2646
2024
Q2 		$17.1M Buy
70,307
+23,449
+50% +$3.7M 0.03% 433
2024
Q1 		$7M Buy
46,858
+22,044
+89% +$3.68M 0.01% 1067
2023
Q4 		$4.75M Buy
+24,814
New +$4.23M 0.01% 1141
2023
Q3 		– Sell
-1,040
Closed -$198K – 4827
2023
Q2 		$198K Buy
+1,040
New +$206K ﹤0.01% 3091
2022
Q1 		– Sell
-3,772
Closed -$640K – 2262
2021
Q4 		$640K Buy
3,772
+104
+3% +$19.3K 0.02% 841
2021
Q3 		$693K Buy
+3,668
New +$688K 0.02% 634
2020
Q1 		– Sell
-1,870
Closed -$215K – 872
2019
Q4 		$215K Buy
+1,870
New +$186K 0.01% 1075
2018
Q3 		$751K Buy
+8,585
New +$864K 0.35% 81

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Walleye Capital's ALNY Position: Q3 2026 in Review

Walleye Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 54% in Q3 2026, buying an estimated $435K and bringing the position to 4,864 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3293.

Walleye Capital first reported a position in ALNY in Q3 2018 and has held it in 17 quarters since. The position peaked at $17.1M in Q2 2024. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Walleye Capital held 4,864 shares of Alnylam Pharmaceuticals worth $1.2M as of Q3 2026.
  • Walleye Capital bought 1,709 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $435K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3293 holding.
  • Walleye Capital first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 17 quarters since.
  • Walleye Capital's Alnylam Pharmaceuticals position peaked at $17.1M in Q2 2024.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.